Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nedizantrep
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Nedizantrep (GDC-6599) is an orally active, small molecule inhibitor of the transient receptor potential cation channel subfamily A member 1 (TRPA1). It is being developed primarily for the treatment of chronic cough and asthma. Nedizantrep acts by selectively inhibiting TRPA1, a sensory ion channel implicated in neurogenic inflammation and cough reflex pathways. The drug has demonstrated potent inhibition of TRPA1 across multiple species and has advanced to Phase II clinical trials for refractory or unexplained chronic cough, with additional studies in asthma. Nedizantrep was developed by Genentech, a subsidiary of F. Hoffmann-La Roche[1][2][3][4][5][6].
- Other names
- nedizantrep
02
Targets
TRPA1 (Transient receptor potential cation channel subfamily A member 1)
Beyond the preview
Go deeper on nedizantrep.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nedizantrep.